Method of controlling coagulation

Patent metadata

Field	Value
Publication number	US-9687529-B2
Application number	US-201214115797-A
Country	US
Kind code	B2
Filing date	May 7, 2012
Priority date	May 5, 2011
Publication date	Jun 27, 2017
Grant date	Jun 27, 2017

Abstract

The present invention relates, in general, to methods of controlling coagulation, and in particular, to methods of effecting neutralizable rapid onset anticoagulation, and to compounds and compositions suitable for use in such methods.

First claim

What is claimed is:

1. A composition comprising at least two agents that directly inhibit more than one step in a coagulation pathway and a carrier, wherein one of the agents is capable of inhibiting Factor X or Factor Xa and the other agent is capable of inhibiting prothrombin or thrombin, wherein the agents are aptamers and the aptamers are 11F7T (SEQ ID NO:2) and R9D-14T (SEQ ID NO: 3 or 13).

2. A composition comprising two agents that each directly inhibit a different step in a coagulation pathway and a carrier, wherein the agents are aptamers and the aptamers are linked to form a single nucleic acid molecule, and wherein the aptamers are 11F7T (SEQ ID NO: 2) and R9D-14T (SEQ ID NO: 3 or 13).

3. The composition of claim 2 , wherein the aptamers comprise a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 19-24.

4. A method of controlling coagulation comprising administering to a subject in need thereof the composition of claim 2 in an amount sufficient to control coagulation.

5. The method according to claim 4 , wherein said subject is a surgery patient or the subject suffers from stroke or deep vein thrombosis.

6. The method according to claim 4 , wherein said subject is undergoing cardiopulmonary bypass surgery or percutaneous coronary intervention.

7. The method of claim 4 , wherein the aptamers comprise a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 19-24.

8. The composition of claim 1 , wherein at least one of the aptamers may be neutralized by an aptamer-specific antidote oligonucleotide or a nucleic acid binding polymer.

9. The composition of claim 8 , wherein the nucleic acid binding polymer is protamine or a cyclodextrin-containing polycation (CDP).

10. The composition of claim 1 , wherein the aptamers are linked to form a single nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 19-24.

11. A method of controlling coagulation comprising administering to a subject in need thereof the composition of claim 1 in an amount sufficient to control coagulation.

12. The method of claim 11 , wherein said subject is a surgery patient or suffers from stroke or deep vein thrombosis.

13. The method of claim 11 , wherein the aptamers are linked to form a single nucleic acid molecule comprising a nucleic acid sequence selected from at least one of SEQ ID NOs: 19-24.

14. A composition comprising two agents that each directly inhibit a different step in a coagulation pathway and a carrier, wherein the agents are aptamers and the aptamers are linked to form a single nucleic acid molecule, and wherein the aptamers comprise a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 15-24.

15. A method of controlling coagulation comprising administering to a subject in need thereof the composition of claim 14 in an amount sufficient to control coagulation.

16. The method of claim 15 , wherein said subject is a surgery patient or suffers from stroke or deep vein thrombosis.

17. The method according to claim 16 , wherein said subject is undergoing cardiopulmonary bypass surgery or percutaneous coronary intervention.

Assignees

• Sullenger Bruce A
• Lohrmann Jens
• Frederiksen James
• Bompiani Kristin
• Univ Duke

Inventors

• Sullenger Bruce A
• Lohrmann Jens
• Frederiksen James
• Bompiani Kristin

Classifications

• A61K31/713

  Double-stranded nucleic acids or oligonucleotides · CPC title

• C12N2310/113

  targeting other non-coding nucleic acids, e.g. antagomirs · CPC title

• C12N2320/53

  reducing unwanted side-effects · CPC title

• C12N2320/31

  Combination therapy · CPC title

• A61K38/36 Primary

  Blood coagulation or fibrinolysis factors · CPC title